MXCT vs NEM · rev $38.6M vs P/E 14, rev $22.67B
MaxCyte Inc (MXCT) versus Newmont Goldcorp Corp (NEM) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Newmont Goldcorp Corp (NEM) is a gold company listed on NYSE.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported NEM revenue for 2025-12-31 was $22.67B. Net income was $7.08B. Revenue was up 21.3% from 2024-12-31 to 2025-12-31. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
MXCT currently screens at market cap $124.3M. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
Not investment advice. Open the MXCT and NEM stock pages for the full models.
Not investment advice.